



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/541,194	06/30/2005	Bertus Noordam	4662-45	8070
	7590 07/24/200 NDERHYE, PC	EXAMINER		
901 NORTH GLEBE ROAD, 11TH FLOOR			LAU, JONATHAN S	
ARLINGTON, VA 22203			ART UNIT	PAPER NUMBER
			1609	
	,		MAIL DATE	DELIVERY MODE
	•		07/24/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/541,194	NOORDAM ET AL.			
Office Action Summary	Examiner	Art Unit			
	Jonathan S. Lau	1609			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING IDENTIFY TO BE A STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING IDENTIFY THE PROPERTY OF THE PROP	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tired will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. nely filed the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 2a) This action is FINAL . 2b) ☑ Thi 3) ☐ Since this application is in condition for allowated closed in accordance with the practice under	s action is non-final. ance except for formal matters, pro	,			
Disposition of Claims					
4)⊠ Claim(s) 1-19 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5)□ Claim(s) is/are allowed. 6)□ Claim(s) is/are rejected. 7)□ Claim(s) is/are objected to. 8)⊠ Claim(s) 1-19 are subject to restriction and/or Application Papers	awn from consideration.				
9)☐ The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) ac		, in the second			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
•					
Attachment(s)					
1) X Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date					
Information Disclosure Statement(s) (PTO/SB/08) Notice of Informal Patent Application Paper No(s)/Mail Date 6) Other:					

Application/Control Number: 10/541,194

Art Unit: 1609

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-5, drawn to a composition comprising 5'-nucleotides and glutamate.

Group II, claim(s) 6-15, drawn to a method of producing a composition comprising 5'-nucleotides.

Group III, claim(s) 16-19, drawn to a method of making a food product incorporating a composition comprising 5'-nucleotides and glutamate.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The only common feature to all groups are a composition comprising 5'-nucleotides and glutamate. The composition of glutamate and 5'-nucleotides does not serve as a special technical feature because it is a well-known product. See Kimizuka et al., col. 1 lines 16-21 (US 4,741,914). The special technical features of the Group II are the specific methods used to produce the composition. The special technical feature of Group III is the incorporation of the 5'-nucleotides and glutamate into a food product.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Art Unit: 1609

The method of treating of cells to release the cell contents comprising RNA disclosed in claim 8.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The claims are deemed to correspond to the species listed above in the following manner:

Claims 6-8 and 10-15 are generic.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: As recited above, because 5'-nucleotides are well-known compounds the special technical features of Group II are the specific methods used to produce the composition. An enzymatic method, a chemical method, or a mechanical method of treating of cells to release the cell contents comprising RNA are different special technical features corresponding to different specific methods used to produce the composition.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the

Application/Control Number: 10/541,194

Art Unit: 1609

requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims.

Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

<u>All</u> claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jonathan S. Lau whose telephone number is 571-270-3531. The examiner can normally be reached on Monday - Thursday, 9 am - 4 pm EST.

Application/Control Number: 10/541,194

Art Unit: 1609

Page 6

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

JSL

Cecilia J. Tsang
Supervisory Patent Examiner
rechnology Center 1600